Cross-Sector entity
Insulet is most often covered alongside AtriCure, which appears in 2 of these 4 stories. The 25-day window averages about 1.1 stories each week. The busiest single day carried 2. The clearest coverage concentration is earnings: 1 of 4 stories, with the rest divided among 3 other categories.
4 verified stories tracked
Last mentioned: Mar 14, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Insulet is most often covered alongside AtriCure, which appears in 2 of these 4 stories. The 25-day window averages about 1.1 stories each week. The busiest single day carried 2. The clearest coverage concentration is earnings: 1 of 4 stories, with the rest divided among 3 other categories. Insulet appears in 4 tracked Cross-Sector stories published from February 18, 2026 through March 14, 2026. Each carries 4 original sources on average.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Insulet. Shared-story counts are live from our verified record — not editorial picks.
IPO Pricing
MiniMed prices 28 million shares at $20.00 per share, raising $560 million.
Analyst Debate
Market analysts debate the valuation of the diabetes unit amid competitive pressures.
Initial Filing
Medtronic's diabetes unit MiniMed seeks up to $784 million in U.S. IPO.
Mid-cap healthcare stocks are seeing a significant re-rating as quantitative models prioritize profitable growth and upward analyst revisions. Following a strong earnings season, the diagnostic and med-tech sub-sectors have emerged as the primary drivers of sector outperformance.
Source: Seeking Alpha · Seeking Alpha
Medtronic’s diabetes subsidiary, MiniMed Group Inc., has priced its initial public offering at $20.00 per share, successfully raising $560 million. The offering of 28 million shares comes in below initial valuation targets but marks a significant strategic pivot for parent company Medtronic plc.
Source: finanznachrichten.de · rttnews.com
A diverse group of mid-to-large cap companies across mining, energy, and healthcare reported stronger-than-expected quarterly results, signaling robust operational efficiency. IAMGOLD and EQT Corporation headlined the session with significant revenue outperformance, reflecting strength in commodity and energy markets.
Insulet and AtriCure reported strong quarterly results, both beating analyst estimates on top and bottom lines. These results highlight robust demand for insulin delivery systems and atrial fibrillation treatments despite broader macroeconomic pressures.
Source: Seeking Alpha · Seeking Alpha
